MedPath

Clopidogrel

Generic Name
Clopidogrel
Brand Names
Duoplavin, Plavix, Zyllt, Clopidogrel BGR (previously Zylagren), Clopidogrel TAD, Clopidogrel ratiopharm, Clopidogrel Zentiva (previously Clopidogrel Winthrop), Clopidogrel Krka, Clopidogrel Krka d.d. (previously Zopya), Clopidogrel Teva (hydrogen sulphate), Clopidogrel HCS, Iscover, Grepid, Clopidogrel Taw Pharma (previously Clopidogrel Mylan), Clopidogrel Viatris (previously Clopidogrel Taw Pharma)
Drug Type
Small Molecule
Chemical Formula
C16H16ClNO2S
CAS Number
113665-84-2
Unique Ingredient Identifier
A74586SNO7
Background

Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke. Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease,

It has been shown to be superior to aspirin in reducing cardiovascular outcomes in patients with cardiovascular disease and provides additional benefit to patients with acute coronary syndromes already taking aspirin.

Clopidogrel was granted FDA approval on 17 November 1997.

Indication

1.用于新近心肌梗死、新近脑卒中或确诊的周围动脉病变患者,可减少新的缺血性脑卒中、心肌梗死和死亡等心脑血管事件的符合终点;

2.用于急性冠状动脉综合征(不稳定心绞痛和非ST段抬高心肌梗死)患者;

3.用于冠状动脉支架置入术后预防支架内血栓形成(与阿司匹林联用)。

Associated Conditions
Acute Coronary Syndrome (ACS), Acute Myocardial Infarction (AMI), Cardiovascular Events, Atherothrombotic events

Prospective, Post-registration, Interventional, Randomized, in Parallel Groups, Multicenter Eurasian Clinical Study of DERIVO®/DERIVO® Mini Aneurysm Embolization Device, Europe-Asia

First Posted Date
2024-05-06
Last Posted Date
2024-05-06
Lead Sponsor
Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health
Target Recruit Count
640
Registration Number
NCT06400940
Locations
🇷🇺

V.A. Almazov Fnmrc, Saint-petersburg, Russian Federation

TADCLOT- a Double Blind Randomized Controlled Trial

Phase 3
Recruiting
Conditions
Myocardial Infarction, Acute
Stent Thrombosis
Interventions
First Posted Date
2024-03-19
Last Posted Date
2024-03-19
Lead Sponsor
National Institute of Cardiovascular Diseases, Pakistan
Target Recruit Count
2200
Registration Number
NCT06318481
Locations
🇵🇰

National Institute of Cardiovascular Diseases, Karachi, SIndh, Pakistan

Pair Antiplatelet THerapy in Ischemic Stroke With Intracranial Artery Stenosis

Phase 4
Not yet recruiting
Conditions
Ischemic Stroke
Intracranial Arteriosclerosis
Secondary Prevention
Antiplatelet Drug
Interventions
First Posted Date
2024-02-06
Last Posted Date
2024-06-18
Lead Sponsor
Sichuan Provincial People's Hospital
Target Recruit Count
1100
Registration Number
NCT06243133
Locations
🇨🇳

Sichuan Provincial People's Hospital, Chengdu, Sichuan, China

Clopidogrel Versus Cilostazol in Ischemic Stroke

Phase 3
Completed
Conditions
Ischemic Stroke
Interventions
First Posted Date
2024-02-05
Last Posted Date
2024-08-20
Lead Sponsor
Kafrelsheikh University
Target Recruit Count
900
Registration Number
NCT06242132
Locations
🇪🇬

Kafr Elsheikh University Hospital, Kafr Ash Shaykh, Egypt

Clopidogrel Versus Cilostazol in Large-vessel Ischemic Stroke

Phase 3
Completed
Conditions
Ischemic Stroke
Interventions
First Posted Date
2024-02-05
Last Posted Date
2024-08-20
Lead Sponsor
Kafrelsheikh University
Target Recruit Count
580
Registration Number
NCT06242145
Locations
🇪🇬

Kafr Elsheikh University Hospital, Kafr Ash Shaykh, Egypt

Tirofiban for Reduction of Thromboembolic Events in Endovascular Unruptured Aneurysm Repair

Phase 2
Recruiting
Conditions
Unruptured Intracranial Aneurysm
Stent-assisted Coiling
Flow Diverter
Thromboembolic Events
Interventions
First Posted Date
2024-02-02
Last Posted Date
2024-03-06
Lead Sponsor
Beijing Tiantan Hospital
Target Recruit Count
190
Registration Number
NCT06238115
Locations
🇨🇳

Beijing Tiantan Hospital, Beijing, China

Effects of Low-dose Ticagrelor vs. Clopidogrel in Stable Patients Undergoing Elective Percutaneous Coronary Intervention

Phase 4
Recruiting
Conditions
Coronary Artery Disease
Interventions
First Posted Date
2024-01-29
Last Posted Date
2025-04-24
Lead Sponsor
University of Florida
Target Recruit Count
50
Registration Number
NCT06228456
Locations
🇺🇸

University of Florida Jacksonville, Jacksonville, Florida, United States

Effect of Tegoprazan on Pharmacodynamics of Clopidogrel in Healthy Subjects

Phase 1
Not yet recruiting
Conditions
Healthy
Interventions
First Posted Date
2023-12-11
Last Posted Date
2023-12-11
Lead Sponsor
HK inno.N Corporation
Target Recruit Count
48
Registration Number
NCT06164834
Locations
🇰🇷

Seoul National University Hospital, Clinical Trial Center, Seoul, Korea, Republic of

Effects of Antiplatelet and Antioxidant Agents on Drusen Progression: A Pilot, Prospective Cohort Study

Phase 3
Recruiting
Conditions
Dry Age-related Macular Degeneration
Interventions
First Posted Date
2023-12-11
Last Posted Date
2023-12-15
Lead Sponsor
Navamindradhiraj University
Target Recruit Count
174
Registration Number
NCT06165068
Locations
🇹🇭

Department of ophthalmology, Faculty of medicine, Vajira hospital, Navamindradhiraj University, Bangkok, Dusit, Thailand

Ticagrelor Versus Clopidogrel in Large Vessel Ischemic Stroke

Phase 3
Completed
Conditions
Ischemic Stroke
Interventions
First Posted Date
2023-11-07
Last Posted Date
2023-12-29
Lead Sponsor
Kafrelsheikh University
Target Recruit Count
580
Registration Number
NCT06120725
Locations
🇪🇬

Kafr Elsheikh University Hospital, Kafr Ash Shaykh, Egypt

© Copyright 2025. All Rights Reserved by MedPath